Market News AIOpen the app

NBIX stock news · Neurocrine Biosciences, Inc.

Stories about Neurocrine Biosciences, Inc. (NBIX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for NBIX

Follow Neurocrine Biosciences, Inc. (NBIX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NBIX
Free on the App Store and Google Play, or on the web.
  1. Nov 13, 2026, 9:38 AM ET · Opinion

    Morgan Stanley raised its price target for Neurocrine Biosciences from $185 to $191 while keeping a 'Neutral' rating.

    Neutral

    Morgan Stanley raised its target for Neurocrine from $185 to $191 and kept its Neutral rating. This is an analyst view, not a company update, so the outlook is unchanged.